New scan spots tiny pancreatic tumors that cause dangerous low blood sugar

NCT ID NCT01916148

AVAILABLE Diagnosis Sponsor: Children's Hospital of Philadelphia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers expanded access to a PET scan using a radioactive tracer called 18F-DOPA to locate small, insulin-producing lesions in the pancreas. It is for patients with congenital hyperinsulinism, Beckwith-Wiedemann syndrome, or insulinoma who have low blood sugar. The goal is to pinpoint the lesion's location to guide surgical removal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-DOPA (a radioactive tracer used in PET scans)
What this could lead to: If successful, this imaging technique could help doctors precisely locate insulin-producing lesions in the pancreas, guiding surgery and potentially curing hypoglycemia.
What could go wrong: This is an expanded access program, not a formal trial, so evidence is limited. The scan may not detect all lesions, and results depend on individual patient factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BECKWITH-WIEDEMANN SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Beckwith-Wiedemann syndrome Congenital Hyperinsulinism familial hyperinsulinism hyperinsulinism hypoglycemia pancreatic insulinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BECKWITH-WIEDEMANN SYNDROME CONGENITAL HYPERINSULINISM (CHI) INSULINOMA

Contacts and locations

Locations

Children's Hospital of Philadelphia
AVAILABLE

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.